Surgical first for ocular bandage

Article

The first ophthalmic surgery in Europe using the CE mark approved I-SIPxAE Adherent Ocular Bandage was conducted in the UK by Dr Daniel Calladine and Mr Richard Packard.

The first ophthalmic surgery in Europe using the CE mark approved I-SIPxAE Adherent Ocular Bandage was conducted in the UK by Dr Daniel Calladine and Mr Richard Packard.

Patients received a foldable IOL with wound-assisted implantation through a 2.2 mm clear corneal incision. No stromal hydration or sutures were employed prior to applying the I-ZIP bandage.

"In a previous clear corneal incision architecture study, we showed that low intra-ocular pressure (IOP) in the immediate postoperative period is associated with incision architectural features that suggest lower structural integrity. All I-ZIP patients had well formed anterior chambers and the incisions were observed with complete coverage of I-ZIP postoperatively," said Mr Packard. Patients were comfortable with normal tearing.

The I-ZIP Adherent Ocular Bandage is a synthetic hydrogel composed of approximately 90% water that can be applied to cornea, sclera and conjunctiva. The hydrogel bandage is applied as a liquid which then polymerizes in situ, forming a soft, adherent, protective barrier over the ocular incision. The bandage is intended to remain on the ocular surface during the normal re-epithelialisation process and subsequently slowly sloughs off into the tears.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.